go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Norgine Limited

Norgine Limited
Chaplin House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS , UK
Telephone: +44 (0)1895 826 600
Fax: +44 (0)1895 825 865
Summary of Product Characteristics last updated on medicines.ie: 19/01/2011
SPC MOVICOL 13.8g sachet, powder for oral solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19/01/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 7 - Marketing authorisation holder
Date of revision of text on the SPC:   09-Sep-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

In section 4.4, the following text was added, "The absorption of other medicinal products could transiently be reduced to an increase in gastro-intestinal transit rate induced by MOVICOL (see section 4.5)."

In section 4.5, the following text was added, "There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics."

In section 4.8, the adverse events were re-formatted according to MeDRA.
Updated on 18/04/2007 and displayed until 19/01/2011
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
Date of revision of text on the SPC:   03/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

 

            2.         Macrogol 3350 (Polyethylene Glycol 3350)    13.125 g

4.1    ………….loading of the rectum and/or colon. confirmed by physical examination of the abdomen and rectum.

4.2    Children below 12 years old: Not recommended. Alternative  Movicol products are available for children.

4.3    Known hypersensitivity to any of these active substances or to any of the excipients. Hypersensitivity to the active ingredients or to any of the excipients.

4.4       Special warnings and precaustions for use

         Diagnosis of impaction/faecal loading of the rectum should be confirmed by physical or radiological examination of the abdomen and rectum.

         There is no clinical trial data on the use of Movicol in children, therefore it is not recommended.

4.5    Macrogol raises the solubility of drugs medicinal products that are soluble in alcohol and relatively insoluble in water.  There is therefore a theoretical possibility that the absorption of such drugs medicinal products could be transiently reduced.

4.7    There is no effect Movicol has no influence on the ability to drive and use machines.

5.1    Pharmacotherapeutic group: Osmotically acting laxatives.

6.1    List of Excipients

         Acesulfame K potassium (E950)

         Lime and lemon flavour*

         (Lime and lemon flavour contains the following constituents: acacia solids, maltodextrin, lime oil, lemon oil, citral, citric acid and water).

6.3    Shelf Life

         The shelf life of the sachets is 3 years.

         Discard any solution not used within Reconstituted solution: 6 hours.

6.4    Reconstituted solution: Store at 2 - 8°C (in a refrigerator and covered).

 

6.5    Nature and contents of container           

Sachet: laminate consisting of four layers: low density polyethylene, aluminium, low density polyethylene and paper.

         13.8g sachets contained in Pack sizes: boxes of 2, 6, 8, 10, 20, 30, 50, 60 or 100 sachets.  Not all pack sizes may be marketed.

6.6    Special precautions for disposal

         None. Any unused solution should be discarded within 6 hours.

10     Date of revision of the text

         August 2002 August 2005 August 2006 March 2007

Updated on 04/12/2006 and displayed until 18/04/2007
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   11/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

 

Section 5.1:

Macrogol 3350 acts by virtue of its osmotic action in the gut, which induces a laxative effect.  . .  Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defaecation. Electrolytes combined with macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in faecal water without net gain or loss of sodium, potassium and water.

 Section 5.2:

Macrogol 3350 is unchanged along the gut.  It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.

Section 10: November 2006
Updated on 22/07/2004 and displayed until 04/12/2006
Reasons for adding or updating:
  • Change to section 10 - Date of revision of the text
Updated on 19/08/2003 and displayed until 22/07/2004
Reasons for adding or updating:
  • New SPC for medicines.ie
Updated on 15/08/2003 and displayed until 19/08/2003
Reasons for adding or updating:
  • New SPC for medicines.ie
Updated on 13/08/2003 and displayed until 15/08/2003
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Potassium Chloride
   Sodium Chloride
   Sodium Hydrogen Carbonate
   Macrogol 3350

Versions

 
19/01/2011 to Current
18/04/2007 to 19/01/2011
04/12/2006 to 18/04/2007
22/07/2004 to 04/12/2006
19/08/2003 to 22/07/2004
15/08/2003 to 19/08/2003
13/08/2003 to 15/08/2003
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo